| OD6 Metals Limited (OD6) ORDINARY FULLY PAID |
Materials |
$29 |
HISTORIC MET TESTING ACHIEVED ACIDSPAR GRADE & HIGH RECOVERY
|
20 May 2026 9:31AM |
$0.150 |
$0.100 |
fallen by
33.33%
|
|
OD6 - Price-sensitive ASX Announcement
Full Release
Key Points
- Historic metallurgical testwork by Union Carbide suggests potential for acid-grade fluorspar production.
- Tests achieved 97.83% CaF2 concentrate, de-risking processing pathways.
- Conventional grinding and flotation identified as effective methods.
- OD6 plans modern testing and application for bulk sample permits.
- Data supports reduced scope and cost for future development studies at Quinn.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Close the Loop Ltd (CLG) ORDINARY FULLY PAID |
Industrials |
$14 |
Strategic Transformation Accelerates
|
20 May 2026 9:31AM |
$0.022 |
$0.026 |
risen by
18.18%
|
|
CLG - Price-sensitive ASX Announcement
Full Release
Key Points
- Sale of ISP Tek Services for US$10 million
- Repayment of US$16 million debt
- Settlement and restructuring of convertible notes
- Bank debt refinance activities in progress
- EBITDA Guidance for FY27 between $14m to $16m
- Strategic transformation focusing on core Packaging and Resource Recovery divisions
- Implementation of AI-driven process improvements
- Strengthened balance sheet and cashflow profile
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patrys Limited (PAB) ORDINARY FULLY PAID |
Health Care |
$29 |
Patrys advances RLS-2202 toward Phase 1 Clinical Trial
|
20 May 2026 9:31AM |
$0.032 |
$0.044 |
risen by
37.50%
|
|
PAB - Price-sensitive ASX Announcement
Full Release
Key Points
- Patrys appoints CMAX as Phase 1A clinical trial site.
- Alithia Life Sciences appointed as CRO.
- Phase 1A study to assess safety, tolerability, and pharmacokinetics.
- Trial set to commence in Q3 2026 pending approvals.
- RLS-2202 targets delirium treatment in acute care settings.
- Program to pursue FDA 505(b)(2) regulatory pathway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Challenger Gold Limited (CEL) ORDINARY FULLY PAID |
Materials |
$329 |
Comments from Chairman Elect Mr Peter Marrone
|
20 May 2026 9:30AM |
$0.130 |
$0.125 |
fallen by
3.85%
|
|
| Freelancer Limited (FLN) ORDINARY FULLY PAID |
Industrials |
$50 |
Appendix 3Y
|
20 May 2026 9:30AM |
$0.140 |
$0.110 |
fallen by
21.43%
|
|
| Kip McGrath Education Centres Limited (KME) ORDINARY FULLY PAID |
Consumer Discretionary |
$22 |
Update - Notification of buy-back - KME
|
20 May 2026 9:29AM |
$0.545 |
$0.420 |
fallen by
22.94%
|
|
| NEXTDC Limited (NXT) ORDINARY FULLY PAID |
Information Technology |
$11,036 |
Ceasing to be a substantial holder
|
20 May 2026 9:28AM |
$14.550 |
$14.530 |
fallen by
0.14%
|
|
| Kaoko Metals Limited (KAO) ORDINARY FULLY PAID |
Materials |
$14 |
Kaoko Investor & Shareholder Webinar Presentation
|
20 May 2026 9:27AM |
$0.450 |
$0.390 |
fallen by
13.33%
|
|
| Thrive Tribe Technologies Limited (1TT) ORDINARY FULLY PAID |
Information Technology |
$14 |
Prospectus Bonus Issue and Target Market Determination
|
20 May 2026 9:26AM |
$0.001 |
$0.003 |
risen by
200%
|
|
1TT - Price-sensitive ASX Announcement
Full Release
Key Points
- Thrive Tribe Technologies Limited is offering a pro-rata non-renounceable entitlement issue of Loyalty Options.
- Eligible Shareholders will receive one Loyalty Option for every fifteen Shares they hold.
- Loyalty Options are exercisable at A$0.003 each and expire on 15 June 2029.
- The Record Date for determining Eligible Shareholders is 26 May 2026.
- The Offer is detailed in a Prospectus issued under section 713 of the Corporations Act.
- The Target Market Determination outlines distribution conditions and reporting requirements for the Loyalty Options.
- No funds will be raised from the Offer as Loyalty Options are issued for nil consideration.
- There is no cooling-off period for the issue of the Loyalty Options.
- The Offer is not underwritten, and no application forms are attached to the Prospectus.
- The Company’s directors have outlined their interests in the Company’s securities in the Prospectus.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MB Gold Limited (MBG) ORDINARY FULLY PAID |
Materials |
$8 |
Exceptional initial assay results from Twin Veins
|
20 May 2026 9:25AM |
$0.190 |
$0.170 |
fallen by
10.53%
|
|
MBG - Price-sensitive ASX Announcement
Full Release
Key Points
- Exceptional initial assay results from Twin Veins Prospect.
- Significant gold intercept of 20m @ 1.74g/t Au from 81m.
- Ongoing drilling with further results expected in three weeks.
- Phase 2 drill program to commence in August.
- MB Gold's Marble Bar Gold Project shows high potential.
- Project location offers excellent infrastructure and accessibility.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID |
Health Care |
$64 |
CLEO Establishes U.S. Reimbursement Pathway
|
20 May 2026 9:25AM |
$0.635 |
$0.470 |
fallen by
25.98%
|
|
COV - Price-sensitive ASX Announcement
Full Release
Key Points
- CLEO establishes U.S. reimbursement pathway using CPT code 81599.
- Immediate market entry and revenue generation post-FDA clearance.
- Reimbursement levels for comparable tests range from ~US$500–$900 per test.
- The pathway allows early prescribing and clinical use in U.S. healthcare settings.
- CLEO plans to apply for a dedicated CPT code to enhance reimbursement consistency.
- The strategy includes generating real-world evidence to support future CPT applications.
- CLEO's plan involves health economics and budget impact model development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Contact Energy Limited (CEN) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Utilities |
$8,201 |
Trading Halt
|
20 May 2026 9:24AM |
$8.200 |
$7.660 |
fallen by
6.59%
|
|
CEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Contact Energy Limited requested a trading halt on 20 May 2026.
- The halt was due to a sale process initiated by Infratil Investments Limited.
- The sale involved a fully underwritten block trade of shares.
- Halt aimed to prevent market distortion and ensure orderly off-market sale.
- Trading expected to resume by market open on 22 May 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$401 |
Update - Notification of buy-back - RG8
|
20 May 2026 9:24AM |
$2.820 |
$2.800 |
fallen by
0.71%
|
|
| GWA Group Limited (GWA) ORDINARY FULLY PAID |
Industrials |
$610 |
Update - Notification of buy-back - GWA
|
20 May 2026 9:23AM |
$2.050 |
$2.300 |
risen by
12.20%
|
|
| Black Bear Minerals Limited (BKB) ORDINARY FULLY PAID |
Materials |
$83 |
Investor Presentation - Canaccord Metals & Mining Conference
|
20 May 2026 9:23AM |
$0.700 |
$0.545 |
fallen by
22.14%
|
|
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$586 |
Update - Notification of buy-back - RG1
|
20 May 2026 9:23AM |
$2.260 |
$2.480 |
risen by
9.73%
|
|
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$5 |
Hydrix positioned for Defence tech expansion
|
20 May 2026 9:23AM |
$0.013 |
$0.004 |
fallen by
73.08%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix has entered a binding contract with NIOA Group to develop counter-Uncrewed Aerial Systems (C-UAS) for Defence applications.
- The contract supports the expansion of Hydrix's expertise in mission-critical embedded electronics and systems integration.
- Hydrix has launched an $8.18 million Entitlement Offer to raise funds for debt reduction and working capital, with a focus on Defence tech growth.
- Commitments have been made to convert $5.113 million of convertible note debt into equity.
- The global counter-UAS market is projected to grow at a CAGR of ~25%, reaching USD $20.3 billion by 2030.
- Hydrix plans to leverage its core engineering capabilities from the MedTech sector to expand its Defence technology offerings.
- Hydrix's strategy includes developing sovereign counter-drone capabilities in response to national Defence needs.
- Hydrix is focused on expanding its presence in Defence technology and pursuing opportunities in embedded intelligence and autonomy-enabling technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$689 |
Future Generation Global Board of Directors Update
|
20 May 2026 9:22AM |
$1.650 |
$1.715 |
risen by
3.94%
|
|
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$5 |
Hydrix raises $3.89m under Institutional Entitlement Offer
|
20 May 2026 9:22AM |
$0.013 |
$0.004 |
fallen by
73.08%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited completed the institutional component of its $8.183 million pro-rata accelerated renounceable entitlement offer.
- The Institutional Entitlement Offer raised approximately $3.89 million at an offer price of $0.005 per share.
- Institutional shareholders did not take up their entitlements, which were sold in the institutional shortfall bookbuild process.
- New institutional investors and family offices subscribed for all available shares under the bookbuild, raising $3,887,349 before offer costs.
- Hydrix's shares are expected to resume normal trading on the ASX on an ex-entitlement basis.
- The Retail Entitlement Offer aims to raise an additional $4.3 million, allowing eligible retail shareholders to subscribe for new shares at the same offer price.
- The proceeds will be used to retire and pay down debt, cover offer costs, and provide working capital for ongoing operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Iceni Gold Limited (ICL) ORDINARY FULLY PAID |
Materials |
$11 |
Exploration Update - Advancing Multiple Targets
|
20 May 2026 9:22AM |
$0.022 |
$0.027 |
risen by
22.73%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$24 |
Noxopharms Sofra assets to be presented at global conference
|
20 May 2026 9:21AM |
$0.064 |
$0.079 |
risen by
23.44%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noxopharm’s Sofra assets will be presented at a global conference.
- The presentation will be by CSL at the Options for the Control of Influenza XIII Conference.
- Focus on improving delivery of self-amplifying mRNA vaccines.
- Sofra is a novel class of drugs targeting immune-related diseases.
- Potential applications include rheumatoid arthritis, lupus, diabetes, and oncology.
- Sofra’s versatility and immune system understanding are attracting industry attention.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Simble Solutions Limited (SIS) ORDINARY FULLY PAID |
Information Technology |
$13 |
Director Appointment
|
20 May 2026 9:21AM |
$0.006 |
$0.006 |
fallen by
0%
|
|
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$17 |
AGM - Chairman and CEO Addresses and Presentation
|
20 May 2026 9:20AM |
$0.350 |
$0.320 |
fallen by
8.57%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $29 million for FY25, up 10% year-on-year.
- Underlying EBITDA of $1.6 million, meeting the top end of guidance.
- Development of Aquila+, an AI platform automating the full radiology workflow.
- Appointment of new CTO and Sales Director to strengthen leadership.
- Continued expansion into the Mexican market, supported by channel partners.
- Approval of CEO option grants and additional share placement capacities.
- Positive outlook for FY26 with expectations to exceed FY25 EBITDA.
- Focus on market expansion, technology development, and financial discipline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Many Peaks Minerals Limited (MPK) ORDINARY FULLY PAID |
Materials |
$135 |
Trading Halt
|
20 May 2026 9:19AM |
$0.930 |
$0.810 |
fallen by
12.90%
|
|
MPK - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Many Peaks Minerals Limited (MPK).
- The halt is pending an announcement regarding a proposed capital raising.
- Trading halt to remain in place until 22 May 2026 or upon the announcement release.
- Request made under ASX Listing Rule 17.1.
- The company is managing its continuous disclosure obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EBR Systems Inc (EBR) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$169 |
Purchasing Agreement Secured with CHRISTUS Health
|
20 May 2026 9:19AM |
$0.505 |
$0.375 |
fallen by
25.74%
|
|
EBR - Price-sensitive ASX Announcement
Full Release
Key Points
- EBR secured a three-year purchasing agreement with CHRISTUS Health.
- CHRISTUS Health is the ninth-largest hospital network in the U.S.
- The agreement covers the WiSE CRT System across 66 hospitals.
- The deal supports EBR's ongoing U.S. commercial rollout.
- CHRISTUS Health's network is primarily located in Texas, Louisiana, and New Mexico.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
